BioPharmaTrend
Latest News
All Topics
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Newsletter
Login/Join
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers
back to Directory

Prescience Insilico

Prescience Insilico logo

Website
https://prescience.in/
Founded
2021

Prescience Insilico is an Indian startup that advances in silico drug development with its PRinS3 platform. The platform integrates advanced algorithms for high-throughput virtual screening, enabling efficient drug discovery processes. Its Artificial Intelligence-Synthetic Molecule Generator (SyMoG/AI) contains 7 pre-trained models for drug targets like Kinase, Nuclear Receptor, etc., and uses a graphical neural network-based AI model.

#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

 

R&D Platform

Besides this, PRinS3’s X-ESS feature automates screening with free energy of binding calculations while supporting multi-target, multi-ligand screening, and utilizing cloud and in-house servers for computational tasks. Prescience Insilico’s approach significantly accelerates the optimization, screening, and evaluation phases in target-based drug development.

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.